Dual inhibition of PI3K and PARP demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts

被引：0
|
作者：
Hall, Tracilyn [1 ]
DiGloria, Celeste [1 ]
Kim, Minji [1 ]
Zhang, Ling [1 ]
Foster, Rosemary [1 ]
Growdon, Whitfield [1 ]
Rueda, Bo [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Cambridge, MA 02138 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 136卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2014.11.033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：398 / 398
页数：1
相关论文
共 50 条
  • [1] PI3K coupled to PARP inhibition demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts
    Hall, T. R.
    DiGloria, C. M.
    Kim, M.
    Zhang, L.
    Foster, R.
    Growdon, W. B.
    Rueda, B. R.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 65 - 65
  • [2] PI3K inhibition induces homologous repair defects in endometrioid endometrial cancer patient derived xenografts leading to synergistic anti-tumor activity with PARP inhibitors
    Rueda, Bo
    Digloria, Celeste
    Hall, Tracilyn
    Foster, Rosemary
    Borger, Darrell
    Growdon, Whitfield
    CANCER RESEARCH, 2015, 75
  • [3] PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
    Bian, X.
    Gao, J.
    Luo, F.
    Rui, C.
    Zheng, T.
    Wang, D.
    Wang, Y.
    Roberts, T. M.
    Liu, P.
    Zhao, J. J.
    Cheng, H.
    ONCOGENE, 2018, 37 (03) : 341 - 351
  • [4] PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
    X Bian
    J Gao
    F Luo
    C Rui
    T Zheng
    D Wang
    Y Wang
    T M Roberts
    P Liu
    J J Zhao
    H Cheng
    Oncogene, 2018, 37 : 341 - 351
  • [5] PI3K pathway dependencies in endometrioid endometrial cancer
    Weigelt, Britta
    Warne, Patricia H.
    Lambros, Maryou B.
    Reis-Filho, Jorge S.
    Downward, Julian
    CANCER RESEARCH, 2013, 73 (08)
  • [6] PI3K Inhibition Sensitizes Patient-derived Tumor Graft Models of Triple Negative Breast Cancer to PARP Inhibition
    Ibrahim, Y.
    Garcia Garcia, C.
    He, L.
    Serra, V.
    Anton, P.
    Guzman, M.
    Cozar, P.
    Ellison, L.
    Scaltriti, M.
    Baslega, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S251 - S252
  • [7] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [8] Combined inhibition of MEK and PI3K elicits anti-tumor activity in human cholangiocarcinoma
    Yang, Jennifer
    Elnaggar, Omar
    Mace, Thomas
    Farren, Matthew
    Young, Gregory
    Lee, Patrice
    Keenan, Kaitlin
    Che, Zheng
    Kaufman, Jacob
    Guttridge, Denis
    Carbone, David
    Timmers, Cynthia
    Bekaii-Saab, Tanios
    Lesinski, Gregory
    CANCER RESEARCH, 2015, 75
  • [9] The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
    Shi, Fei
    Zhang, Jinying
    Liu, Hongyu
    Wu, Liangliang
    Jiang, Hongyu
    Wu, Qiyan
    Liu, Tianyi
    Lou, Meiqing
    Wu, Hao
    ONCOTARGET, 2018, 9 (01) : 706 - 717
  • [10] PI3K inhibitors reduce breast cancer tumor growth and enhance anti-tumor leukocyte activity
    Lavender, Nicole
    Yang, Jinming
    Sai, Jiqing
    Novitskiy, Sergey
    Horton, Linda
    Johnson, Andrew
    Abramson, Vandana
    Mayer, Ingrid
    Meszoely, Ingrid
    Kelley, Mark
    Richmond, Ann
    CANCER RESEARCH, 2016, 76
12345